ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده: مورد

Medications associated with acquired perforating dermatoses

Medications associated with acquired perforating dermatoses
Azathioprine[1]
Bevacizumab[2]
Indinavir[3]
Leflunomide[4]
Lenalidomide[5]
Lenvatinib[6]
Natalizumab[7]
Necitumumab[8]
Nilotinib[9]
PD-1 inhibitors[10]
Sirolimus[11]
Sorafenib[12,13]
Telaprevir[14]
TNF inhibitors[15]
Vemurafenib[16]
PD-1: programmed cell death protein 1; TNF: tumor necrosis factor.
References:
  1. Grillo E, Vano-Galván S, Moreno C, Jaén P. Perforating dermatosis in a patient receiving azathioprine. Indian J Dermatol 2013; 58:158.
  2. Vano-Galvan S, Moreno C, Medina J, et al. Perforating dermatosis in a patient receiving Bevacizumab. J Eur Acad Dermatol Venereol 2009; 23:972.
  3. Calista D, Morri M. Acquired reactive perforating collagenosis induced by indinavir in 2 patients with HIV disease. Eur J Dermatol 2008; 18:84.
  4. Keeley JM, Pavlidakey P, Sami N. Perforating disorder secondary to leflunomide and review of the literature of medications associated with perforating disorder. Dermatol Online J 2018; 24:7.
  5. Kuiper EM, Kardaun SH. Late onset perforating folliculitis induced by lenalidomide: a case report. Br J Dermatol 2015; 173:618.
  6. Sato-Sano M, Cury-Martins J, Macarenco R, et al. Perforating dermatosis associated with multikinase inhibitors: Report of two cases, including one associated with lenvatinib. J Dtsch Dermatol Ges 2018; 16:1486.
  7. Piqué-Duran E, Equí P, García-Vázquez O. Acquired perforating dermatosis associated with natalizumab. J Am Acad Dermatol 2013; 68:e185.
  8. Kimura A, Kosumi H, Natsuga K, et al. Acquired perforating dermatosis induced by necitumumab. J Eur Acad Dermatol Venereol 2022; 36:e822.
  9. Llamas-Velasco M, Steegmann JL, Carrascosa R, et al. Perforating folliculitis in a patient treated with nilotinib: A further evidence of C-kit involvement. Am J Dermatopathol 2014; 36:592.
  10. Liu X, Wang H, Wan Y, et al. Acquired perforating dermatosis induced by pd-1 inhibitor: A case report. Am J Dermatopathol 2021; 43:942.
  11. Lübbe J, Sorg O, Malé PJ, et al. Sirolimus-induced inflammatory papules with acquired reactive perforating collagenosis. Dermatology 2008; 216:239.
  12. Batalla A, Menendez L, Blay P, Curto JR. Delayed onset perforating folliculitis associated with sorafenib. Australas J Dermatol 2014; 55:233.
  13. Wolber C, Udvardi A, Tatzreiter G, et al. Perforating folliculitis, angioedema, hand-foot syndrome--Multiple cutaneous side effects in a patient treated with sorafenib. J Dtsch Dermatol Ges 2009; 7:449.
  14. Pernet C, Pageaux GP, Guillot B, et al. Telaprevir-induced acquired perforating dermatosis. JAMA Dermatol 2014; 150:1371.
  15. Gilaberte Y, Coscojuela C, Vazquez C, et al. Perforating folliculitis associated with tumor necrosis factor-alpha inhibitors administered for rheumatoid arthritis. Br J Dermatol 2007; 156:368.
  16. Shiraishi K, Masunaga T, Tohyama M, Sayama K. A case of perforating folliculitis induced by vemurafenib. Acta Derm Venereol 2019; 99:230.
Graphic 109810 Version 4.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟